Zusammenfassung
Auf der Basis neuerer epidemiologischer und interventioneller Studien wird die Notwendigkeit von Screening-Untersuchungen und Therapie für Prädiabetes diskutiert. In diesem Artikel werden die Grundlagen dafür nach Evidenz-Kriterien untersucht.
Hierbei wird auf die makrovaskulären Komplikationen fokussiert, da diese die Prognose eines Diabetikers am stärksten bestimmen.
Zwar steigt die Häufigkeit makrovaskulärer Organschäden in Abhängigkeit von Dauer und Intensität der häufig lange nicht bemerkten Stoffwechselstörung schon vor der Diabetes-Diagnose an, bislang konnte aber durch Studien eine Prognoseverbesserung durch strengere Stoffwechselkontrolle nicht bewiesen werden.
Ein generelles Screening auf Prädiabetes ist auf dem Boden der derzeit vorliegenden Studien deswegen nicht empfehlenswert.
Abstract
The results of recent epidemiological and interventional studies lead to a discussion about screening and treatment for pre-diabetes. This article reviews the relevant evidence for such a new strategy.
Although the rise in degree and frequency of macrovascular complications correlates with time of impaired glucose metabolism before manifestation of diabetes type 2, no trials could show any significant effect of intensive blood sugar control against these complications. Screening for pre-diabetes is therefore not generally recommended.
Schlüsselwörter
Diabetes mellitus - NIDDM - Diabetes Prävention - gestörte Glukose-Toleranz - Prädiabetes - Kardiovaskuläres Risiko - Arcabose - Melformin - Nüchtern-Blutzucker
Key words
Diabetes mellitus - NIDDM - diabetes prevention - impaired glucose tolerance - prediabetes - cardiovascular risk - acarbose - metformin - impaired fasting glucose
Literatur
-
1 Blech J. Erfundene Krankheiten. „Der Spiegel” 33/2003
-
2
JNC-7-Report mit der Empfehlung, nur Blutdruckwerte < 120/80 mm Hg als normal zu bezeichnen.
JAMA.
2003;
289
2560-2572
-
3
American Diabetes Association .
Diabetes Care.
2003;
26
645-649
-
4 NCEP 2001. NIH Publication No. 01-3305. Mai 2001
-
5
US Preventive Services Task Force .
Screening for Type 2 Diabetes Mellitus in Adults: Recommendations and Rationale.
Ann Intern Med.
2003;
138
212-214
-
6
American Diabetes Association and National Institute of Diabetes, Digestive And Kidney Diseases .
The Prevention or Delay of Type 2 Diabetes.
Diabetes Care.
2002;
25
742-749
-
7 WHO .Screening for Type II Diabetes. http://www.who.int/ncd/dia/dia_publications.htm besucht am 15.11.2003
-
8
Hauner. et al .
Schätzung der Diabeteshäufigkeit in der Bundesrepublik Deutschland anhand von Krankenkassendaten.
DMW.
1992;
117
645-650
-
9
Ratzmann.
Eine Analyse von alters- und geschlechtsspezifischer Diabetesprävalenz.
Akt Endokr Stoffw.
1991;
12
220-223
-
10
Rathmann, Löwel.
High prevalence of undiagnosed diabetes mellitus in Southern Germany: The KORA survey 2000.
Diabetologia.
2003;
46
182-189
-
11
Stövring. et al .
Rising prevalence of diabetes: evidence from a Danisk pharmaco-epidemiological database.
Lancet.
2003;
362
537-538
-
12
Haffner, Lehto, Rönnemaa, Pyörälä, Laakso.
Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med.
1998;
339
229-234
-
13
Evans, Wang, Morris.
Comparison of cardiovascular risk between patients with type 2 diabetes and those who had ha a myocardial infarction.
BMJ.
2002;
324
939-944
-
14
Coutinho, Wang, Gerstein, Yusuf.
The relationship between glucose and incident cardiovascular events. A metaregression analyses of published data from 20 studies of 95 783 individuals followed for 12.4 years.
Diabetes Care.
1999;
22
233-240
-
15
Stratton. et al .
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35).
BMJ.
2000;
321
405-412
-
16
Hu. et al .
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. The Nurses Health Study.
Diabetes Care.
2002;
25
1129-1134
-
17
NCEP ATP III.
JAMA.
2001;
285
2486-2497
-
18 The Metabolic Syndrome. Diabetes Mellitus Interagency Coordinating Committee Meeting. National Institutes of Health Campus. Natcher Conference Center, Conference Room A. Bethesda, Maryland, February 25, 2003
-
19
World Health Organisation Study Group .
Diabetes Mellitus.
WHO Tech Rep Ser.
1985;
727
-
20
The expert committee on the diagnosis and classification of diabetes mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus.
Diabetes Care.
1997;
20
1183-1197
-
21 Nationale Versorgungsleitlinie Diabetes Version 1.7.2002.
www.akdae.de oder www.awfm-online.de
-
22
DECODE study group .
Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria.
Lancet.
1999;
354
617-621
-
23 RR = Relatives Risiko: Die Wahrscheinlichkeit, vorzeitig zu versterben, ist bei einem RR 1,8 um den Faktor 1,8 erhöht.
-
24
Haffner. et al .
Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?.
JAMA.
1990;
263
2893-2898
-
25
Fasting and postchallenge glycemia and cardiovascular disease risk - the Framingham offspring study.
Diabetes Care.
2002;
25
1845-1850
-
26
DECODE Study group .
Will the new diagnostic criteria for diabetes melltus change phenotype of patients with diabetes? Reanalysis of European epidemiological data.
BMJ.
1998;
317
371-375
-
27
Feskens. et al .
Intra- and interindividual variability of glucose tolerance in an elderly population.
J Clin Epidemiology.
1991;
40
947-953
-
28
Mc Donald. et al .
Reproducibility of the oral glucose tolerance test.
Diabetes.
1965;
14
473-480
-
29
Olefsky. et al .
Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart.
Diabetes.
1974;
23
449-453
-
30
Mooy. et al .
Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study.
Diabetologia.
1996;
39
298-305
-
31
Ko. et al .
The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors.
Ann Clin Biochem.
1998;
35
62-67
-
32
Burke. et al .
Reversion from type 2 diabetes to nondiabetic status: influence of the 1997 American Diabetes Association criteria.
Diabetes Care.
1998;
21
1266-1270
-
33
Eschwege. et al .
Reproducibility of the diagnosis of diabetes over a 30-month follow-up: the Paris Prospective Study.
Diabetes Care.
2001;
24
1941-1944
-
34
Eschwege. et al .
From Policemen to policies: what is the future for 2-h glucose? The Kelly West Lecture.
Diabetes Care.
2001;
24
1945-1950
-
35
Gabir. et al .
The 1997 American Diabetes Association and 1999 World Health Organization Criteria for hyperglycaemia in the diagnosis and prediction of diabetes.
Diabetes Care.
2000;
23
1108-1112
-
36
Pan, Li, Hu, Wang, Yang, An, Hu, Lin, Xiao. et al .
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Quing IGT and Diabetes Study.
Diabetes Care.
1997;
20
537-544
-
37
Tuomilehto, Lindström, Eriksson, Valle. et al .
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
N Engl J Med.
2001;
344
1343-1350
-
38
Diabetes Prevention Program Research Group .
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med.
2002;
346
393-402
-
39
Chiasson, Josse, Gomis, Hanefeld, Karasik, Laakso.
Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomised trial.
Lancet.
2002;
359
2072-2077
-
40 NN. STOP-NIDDM-Studie mit Acarbose. Schlamperei, Manipulation, Irreführung. Arzneimitteltelegramm 2003; 8: 73
-
41
UKPDS 33.
Lancet.
1998;
352
837-851
-
42
UK Prospective Diabetes Study Group .
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet.
1998;
352
854-865
-
43
de Lorgeril. et al .
Lyon Diet Heart Study.
Circulation.
1999;
99
779-785
-
44
Singh. et al .
Indo-Mediterranean Diet Heart Study.
Lancet.
2002;
360
1455-1461
-
45
Ornish. et al .
JAMA.
1998;
280
2001-2007
-
46
Haskell. et al .
SCRIP = Stanford Coronary Risk Intervention Project.
Circulation.
1994;
89
975-990
-
47
Eriksson K F, Lindgäde P.
No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise.
Diabetologia.
1998;
41
1010-1016
Günther Egidi
Huchtinger Heerstr. 41
28259 Bremen
Phone: 04 21-5 79 76 75
Email: familie-egidi@nord-com.net
